文献速递肾小球疾病遗传性与小管间质肾病

IgG-FH1-5融合蛋白可调节C3肾小球病补体活性

Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains.
PubMed 文献 · Kidney Int · 2020-10-28

在因子H缺陷小鼠模型中,两种含FH1-5的融合蛋白(IgG-FH1-5和Anti-P-FH1-5)均能同等程度升高血浆C3并减少肾小球C3沉积。IgG-FH1-5可恢复循环替代途径活性,且血浆properdin水平是因子H缺陷中C5转化酶活性的敏感标志物。

要点

  • IgG-FH1-5与Anti-P-FH1-5均升高血浆C3并减少肾小球C3沉积,效果相当。
  • 靶向properdin并非FH1-5调节C3激活所必需。
  • 血浆properdin水平是因子H缺陷中C5转化酶活性的敏感标志物。

核心结论

  • IgG-FH1-5可恢复Cfh-/-小鼠循环替代途径活性并减少肾小球C3沉积。
  • 血浆properdin水平是因子H缺陷中C5转化酶活性的敏感标志物。
  • 免疫球蛋白偶联的FH1-5蛋白可能成为C3肾小球病的潜在疗法。

研究设计与样本

  • 使用因子H缺陷(Cfh-/-)小鼠模型评估两种融合蛋白的疗效。
  • 两种蛋白分别为IgG-FH1-5(非靶向小鼠免疫球蛋白)和Anti-P-FH1-5(抗小鼠properdin抗体)。

主要发现

  • 两种蛋白均升高血浆C3并减少肾小球C3沉积,程度相当。
  • IgG-FH1-5给药后血浆C3水平与因子B水平变化时序相关。
  • 血浆C5水平与血浆properdin水平变化相关。
  • 血浆C5和properdin水平的升高持续时间长于C3和因子B的升高。
  • IgG-FH1-5在加速性血清肾毒性肾炎中减轻Cfh-/-小鼠肾损伤。

临床怎么用

  • IgG-FH1-5可能通过较长血浆半衰期成为C3肾小球病的潜在治疗选择。
  • 血浆properdin水平可作为因子H缺陷中C5转化酶活性的敏感监测标志物。

局限性

  • 研究基于Cfh-/-小鼠模型,尚未在人体中验证。
  • 原文未报告样本量、P值等详细统计信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

C3 glomerulopathy is characterized by accumulation of complement C3 within glomeruli. Causes include, but are not limited to, abnormalities in factor H, the major negative regulator of the complement alternative pathway. Factor H-deficient (Cfh-/-) mice develop C3 glomerulopathy together with a reduction in plasma C3 levels. Using this model, we assessed the efficacy of two fusion proteins containing the factor H alternative pathway regulatory domains (FH1-5) linked to either a non-targeting mouse immunoglobulin (IgG-FH1-5) or to an anti-mouse properdin antibody (Anti-P-FH1-5). Both proteins increased plasma C3 and reduced glomerular C3 deposition to an equivalent extent, suggesting that properdin-targeting was not required for FH1-5 to alter C3 activation in either plasma or glomeruli. Following IgG-FH1-5 administration, plasma C3 levels temporally correlated with changes in factor B levels whereas plasma C5 levels correlated with changes in plasma properdin levels. Notably, the increases in plasma C5 and properdin levels persisted for longer than the increases in C3 and factor B. In Cfh-/- mice IgG-FH1-5 reduced kidney injury during accelerated serum nephrotoxic nephritis. Thus, our data demonstrate that IgG-FH1-5 restored circulating alternative pathway activity and reduced glomerular C3 deposition in Cfh-/- mice and that plasma properdin levels are a sensitive marker of C5 convertase activity in factor H deficiency. The immunoglobulin conjugated FH1-5 protein, through its comparatively long plasma half-life, may be a potential therapy for C3 glomerulopathy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Gilmore AC, Zhang Y, Cook HT, et al. Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains. Kidney Int. 2020. PMID: 33129896. doi:10.1016/j.kint.2020.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。